| Overview |
| bs-1565R-Cy3 |
| APCDD1 Polyclonal Antibody, Cy3 Conjugated |
| WB |
| Human, Mouse, Rat |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human APCDD1 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 147495 |
| adenomatosio polyposis coli down-regulated 1; Adenomatosis polyposis coli down regulated 1; Adenomatosis polyposis coli down regulated 1 protein; APCDD 1; B7323; DRAPC1; FP7019; Protein APCDD1; APCD1_HUMAN. |
| APCDD1 is a novel protein that has been shown to be a target of Wnt/beta catenin signaling pathway in cancer cell lines. APCDD1 is overexpressed in colorectal carcinogenesis and is deregulated in CTNNB1 mutated Wilms tumors.[FUNCTION] Probably plays a role in colorectal tumorigenesis. May be a developmental target gene of the Wnt/Beta-catenin pathway.[SUBCELLULAR LOCATION] Membrane; Single-pass type I membrane protein (Potential). [TISSUE SPECIFICITY] Abundantly expressed in heart, pancreas, prostate and ovary. Moderately expressed in lung, liver, kidney, spleen, thymus, colon and peripheral lymphocytes. [INDUCTION] Transcriptionally regulated by the CTNNB1/TF7L2complex. |
| Application Dilution |
| WB |
1:500-2000 |
Powered by Bioz